Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
Avidity is committed to delivering a new class of pioneering RNA therapeutics called Antibody Oligonucleotide Conjugates for serious, genetic neuromuscular diseases. The proposed acquisition will bring Aviditys late-stage neuroscience programs into Novartis and provide Novartis access to a differentiated RNA-targeting delivery platform.
